Adding Ovarian Suppression to Tamoxifen for Premenopausal Women With Hormone Receptor-Positive Breast Cancer After Chemotherapy: An 8-Year Follow-Up of the ASTRRA Trial
- Authors
- Baek, Soo Yeon; Noh, Woo Chul; Ahn, Sei-Hyun; Kim, Hyun-Ah; Ryu, Jai Min; Kim, Seung Il; Lee, Eun-Gyeong; Im, Seock-Ah; Jung, Yongsik; Park, Min Ho; Park, Kyong Hwa; Kang, Su Hwan; Jeong, Joon; Park, Eunhwa; Kim, Sung Yong; Lee, Min Hyuk; Kim, Lee Su; Lim, Woosung; Kim, Seonok; Kim, Hee Jeong
- Issue Date
- Nov-2023
- Publisher
- LIPPINCOTT WILLIAMS & WILKINS
- Citation
- JOURNAL OF CLINICAL ONCOLOGY, v.41, no.31, pp 4864 - +
- Journal Title
- JOURNAL OF CLINICAL ONCOLOGY
- Volume
- 41
- Number
- 31
- Start Page
- 4864
- End Page
- +
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/25675
- DOI
- 10.1200/JCO.23.00557
- ISSN
- 0732-183X
1527-7755
- Abstract
- PURPOSETo determine the updated long-term outcomes of the Addition of Ovarian Suppression to Tamoxifen in Young Women With Hormone-Sensitive Breast Cancer Who Remain Premenopausal or Regain Vaginal Bleeding After Chemotherapy (ASTRRA) trial.PATIENTS AND METHODSThis study is a post-trial follow-up of the ASTRRA trial, involving 1,483 premenopausal women younger than 45 years treated with definitive surgery after completing adjuvant or neoadjuvant chemotherapy for estrogen receptor-positive breast cancer. Patients were randomly assigned in a 1:1 ratio to complete 5 years of tamoxifen (TAM) alone (TAM-only) or 5 years of TAM with ovarian function suppression (OFS) for 2 years (TAM + OFS). The primary end point was disease-free survival (DFS), and the secondary end point was overall survival (OS).RESULTSAt 106.4 months of median follow-up, there was a continuous significant reduction in the DFS event rate in the TAM + OFS group. The 8-year DFS rate was 85.4% in the TAM + OFS group and 80.2% in the TAM-only group (hazard ratio [HR], 0.67; 95% CI, 0.51 to 0.87). There were no significant differences in OS between the two groups. The OS rate was 96.5% in the TAM + OFS group and 95.3% in the TAM-only group (HR, 0.78; 95% CI, 0.49 to 1.25).CONCLUSIONAdding OFS for 2 years to adjuvant TAM with a longer follow-up resulted in consistent DFS benefits, suggesting that adding OFS to TAM should be considered for patients who remain in a premenopausal state or resume ovarian function after chemotherapy.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of General Surgery > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/25675)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.